Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Gut - 1 Oct 2015

Liu David S H, Read Matthew, Cullinane Carleen, Azar Walid J, Fennell Christina M, Montgomery Karen G, Haupt Sue, Haupt Ygal, Wiman Klas G, Duong Cuong P, Clemons Nicholas J, Phillips Wayne A

Abstract excerpt

OBJECTIVES: p53 is a critical tumour suppressor and is mutated in 70% of oesophageal adenocarcinomas (OACs), resulting in chemoresistance and poor survival. APR-246 is a first-in-class reactivator of mutant p53 and is currently in clinical trials. In this study, we characterised the activity of APR-246 and its effect on p53 signalling in a large panel of cell line xenograft (CLX) and patient-derived xenograft...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Blotting, Western

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Esophageal Neoplasms

Share to Neoplasms, Experimental

Share to RNA, Neoplasm

Share to Tumor Cells, Cultured

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 26187504
DOI: 10.1136/gutjnl-2015-309770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.PMID 26187504Read ↗

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.Semantic proximity Read ↗

APR-246 Enhances Colorectal Cancer Sensitivity to RadiotherapySemantic proximity Read ↗

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than <i>TP53</i> mutation statusSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

Mutant p53 reactivation by small molecules makes its way to the clinic.Semantic proximity Read ↗

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.Semantic proximity Read ↗

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Semantic proximity Read ↗

p53 reactivating small molecule PRIMA‑1MET/APR‑246 regulates genomic instability in MDA‑MB‑231 cells.Semantic proximity Read ↗

APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.Semantic proximity Read ↗

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.Semantic proximity Read ↗

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.